Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia

Ralph Boccia; Imtiaz A. Malik; Vinay Raja; Stephen Kahanic; Randall Liu; Tom Lillie; Dianne Tomita; Billy Clowney; Peter Silberstein

doi:10.1634/theoncologist.11-4-409

Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia

Ralph Boccia, Imtiaz A. Malik, Vinay Raja, Stephen Kahanic, Randall Liu, Tom Lillie, Dianne Tomita, Billy Clowney, Peter Silberstein

Department of Medicine

Research output: Contribution to journal › Article

35 Scopus citations

Abstract

Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin

Original language	English (US)
Pages (from-to)	409-417
Number of pages	9
Journal	Oncologist
Volume	11
Issue number	4
DOIs	https://doi.org/10.1634/theoncologist.11-4-409
State	Published - Apr 1 2006

Fingerprint

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Cite this

Boccia, R., Malik, I. A., Raja, V., Kahanic, S., Liu, R., Lillie, T., Tomita, D., Clowney, B., & Silberstein, P. (2006). Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist, 11(4), 409-417. https://doi.org/10.1634/theoncologist.11-4-409

@article{10a7e518d7584ffdadb196d51f208645,

title = "Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia",

abstract = "Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin ",

author = "Ralph Boccia and Malik, {Imtiaz A.} and Vinay Raja and Stephen Kahanic and Randall Liu and Tom Lillie and Dianne Tomita and Billy Clowney and Peter Silberstein",

year = "2006",

month = apr

day = "1",

doi = "10.1634/theoncologist.11-4-409",

language = "English (US)",

volume = "11",

pages = "409--417",

journal = "Oncologist",

issn = "1083-7159",

publisher = "AlphaMed Press",

number = "4",

}

TY - JOUR

T1 - Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia

AU - Boccia, Ralph

AU - Malik, Imtiaz A.

AU - Raja, Vinay

AU - Kahanic, Stephen

AU - Liu, Randall

AU - Lillie, Tom

AU - Tomita, Dianne

AU - Clowney, Billy

AU - Silberstein, Peter

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin

AB - Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin

UR - http://www.scopus.com/inward/record.url?scp=33645784831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645784831&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.11-4-409

DO - 10.1634/theoncologist.11-4-409

M3 - Article

C2 - 16614237

AN - SCOPUS:33645784831

VL - 11

SP - 409

EP - 417

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 4

ER -

Access to Document

10.1634/theoncologist.11-4-409